# Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye

> **NCT02908282** · NA · COMPLETED · sponsor: **TRB Chemedica AG** · enrollment: 81 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DEVICE:** REMOGEN OMEGA
- **DEVICE:** Povidone

## Key facts

- **NCT ID:** NCT02908282
- **Lead sponsor:** TRB Chemedica AG
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2018-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908282, "Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02908282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*